JP2024532453A5 - - Google Patents

Info

Publication number
JP2024532453A5
JP2024532453A5 JP2024513543A JP2024513543A JP2024532453A5 JP 2024532453 A5 JP2024532453 A5 JP 2024532453A5 JP 2024513543 A JP2024513543 A JP 2024513543A JP 2024513543 A JP2024513543 A JP 2024513543A JP 2024532453 A5 JP2024532453 A5 JP 2024532453A5
Authority
JP
Japan
Prior art keywords
hiv infection
gene
gene coding
hiv
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/115831 external-priority patent/WO2023030315A1/zh
Publication of JP2024532453A publication Critical patent/JP2024532453A/ja
Publication of JP2024532453A5 publication Critical patent/JP2024532453A5/ja
Pending legal-status Critical Current

Links

JP2024513543A 2021-08-30 2022-08-30 エイズウイルス感染の遺伝子治療用の遺伝子配列構築体 Pending JP2024532453A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/115422 2021-08-30
CN2021115422 2021-08-30
PCT/CN2022/115831 WO2023030315A1 (zh) 2021-08-30 2022-08-30 一种用于艾滋病病毒感染基因治疗的基因序列构建体

Publications (2)

Publication Number Publication Date
JP2024532453A JP2024532453A (ja) 2024-09-05
JP2024532453A5 true JP2024532453A5 (cg-RX-API-DMAC7.html) 2025-09-17

Family

ID=85410861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513543A Pending JP2024532453A (ja) 2021-08-30 2022-08-30 エイズウイルス感染の遺伝子治療用の遺伝子配列構築体

Country Status (7)

Country Link
US (1) US20240352096A1 (cg-RX-API-DMAC7.html)
EP (1) EP4397764A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532453A (cg-RX-API-DMAC7.html)
CN (1) CN118382699A (cg-RX-API-DMAC7.html)
AU (1) AU2022337765A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230810A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023030315A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4397748A4 (en) * 2021-08-30 2025-09-17 Kanglin Biotechnology Hangzhou Co Ltd GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION
WO2024044892A1 (zh) * 2022-08-29 2024-03-07 上海目镜生物医药科技有限公司 一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
WO2025081292A1 (zh) * 2023-10-16 2025-04-24 北京脑科学与类脑研究所 纳米抗体辅助的蛋白或多肽表达系统及制备和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101500615A (zh) * 2006-08-17 2009-08-05 霍夫曼-拉罗奇有限公司 针对ccr5的抗体和抗融合肽的缀合物
CA2794632A1 (en) * 2010-05-03 2011-11-10 New York Blood Center, Inc. Bifunctional molecules for inactivating hiv and blocking hiv entry
CN103282385A (zh) * 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
CN104004092B (zh) * 2014-06-05 2015-07-29 深圳市第三人民医院 单基因编码的双或多价特异性抗hiv免疫粘附素
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US20200157192A1 (en) * 2017-05-10 2020-05-21 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
JP7377802B2 (ja) * 2017-12-20 2023-11-10 レンティジェン・テクノロジー・インコーポレイテッド 免疫療法を用いてhiv/aidsを処置するための組成物および方法
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
CN114645066B (zh) * 2020-12-21 2023-08-25 康霖生物科技(杭州)有限公司 一种用于艾滋病基因治疗的核酸构建体
EP4397748A4 (en) * 2021-08-30 2025-09-17 Kanglin Biotechnology Hangzhou Co Ltd GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION

Similar Documents

Publication Publication Date Title
CN107847591B (zh) 多价人免疫缺陷病毒抗原结合分子及其应用
EP3365366B1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EP2571898B1 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
JP2022101682A (ja) HIV gp120を標的化する抗体および使用方法
JP2020096630A5 (cg-RX-API-DMAC7.html)
JP2020120689A5 (cg-RX-API-DMAC7.html)
JP2024532426A5 (cg-RX-API-DMAC7.html)
JP2025508118A (ja) 新規免疫調節剤の開発および使用
WO2024125180A1 (zh) 抗cd155的抗体及其应用
EP4397764A1 (en) Gene sequence construct for gene therapy of human immunodeficiency virus infection
CN118184774A (zh) 中和SARS-CoV-2及变异株的全人源抗体及应用
EP4397748A1 (en) Gene sequence construct for gene therapy for hiv infection
CN111944054A (zh) 抗bcma的car及其表达载体和应用
CN121816190A (zh) 双靶标car-t细胞在治疗b细胞自身免疫性疾病中的用途
EP4588937A1 (en) Use of nkg2d-based cell adapter molecule in removal of aging cells
CN112661852A (zh) 针对乙肝病毒的双特异性抗体及其应用
CN111944053A (zh) 抗bcma的car及其表达载体和应用
JP2018534915A5 (cg-RX-API-DMAC7.html)
US20240050567A1 (en) Modified immune effector cell and use thereof
CA2481325C (en) Anti-hiv composition, production method thereof and medicament
WO2023279803A1 (zh) Rbv的蛋白结合分子及其用途
CN106892979A (zh) 一种全人源抗h7n9病毒的中和抗体
WO2022122788A1 (en) Multispecific antibodies against severe acute respiratory syndrome coronavirus 2
Nakamura et al. Virolysis and in vitro neutralization of HIV-1 by humanized monoclonal antibody hNM-01
JPWO2010087131A1 (ja) Hiv複製抑制剤、及びその利用